Amylx Pharmaceuticals Inc vs Old Dominion Freight Line Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Old Dominion Freight Line Inc trades at $209.64 (market cap $44.07B). The key difference: Old Dominion Freight Line Inc is far larger — about 17.4× Amylx Pharmaceuticals Inc's market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | ODFL | |
|---|---|---|
Market Cap | $2.53B | $44.07B |
Sector | Health | Industrials |
52-Week High | $24.19 | $248.73 |
52-Week Low | $7.82 | $126.29 |
Enterprise Value | $2.28B | $43.81B |
Dividend Yield | — | 0.55% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
ODFL stock trades at $216.36, up 2.34% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $1.68 versus $1.54 expected, driven by yield improvements and cost discipline. The company maintains robust profitability with a net income margin of 19.44% and ROE of 24.82%, though revenue has declined from $6.3B in 2022 to $5.5B in 2025. Analyst consensus price target is $239.85, suggesting upside potential.
Outlook is mixed: earnings momentum and a solid balance sheet support growth, but high valuation ratios (P/E of 41.6) and freight volume pressures pose risks. Investors should weigh the premium pricing against operational efficiency gains and market recovery prospects.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →